The topics for discussion include:
- Patent legislation, both from the standpoint of a critical analysis of pending bills and whether other legislation may better reach the results sought;
- Section 101 patent eligibility after Bilski, Prometheus, and Myriad; the law of obviousness post KSR;
- De novo review of claim construction rulings;
- The implications of the Medtronic case now before the Supreme Court on patent licensing in the wake of Medimmune;
- The impact of the Federal Circuit’s decision in Fresenius v. Baxter on patent validity challenges; and
- The ITC’s domestic industry requirement; and proposed reform of appellate jurisdiction in patent cases.
People
Related Insights
June 4, 2025
Innovative Technology Insights
Quantum Computer Hardware: How Quantum Computers Are Implemented
In the previous article titled “The Basics: How Quantum Computers Work and Where the Technology is Heading,” we provided an overview of…
June 4, 2025
Foley Ignite
M&A Disputes Set to Rise in Latin America: How Savvy Investors Are Protecting Themselves
As deal activity shows signs of rebounding in 2025, investors are bracing for an increase in M&A-related disputes globally, and Latin…
June 3, 2025
Foley Corporate Governance Update
Texas Senate Bill 2337: Protecting Texas Companies and Their Directors, Shareholders and Boards from Proxy Advice Not in the Financial Interests of Shareholders
On June 2, 2025, the Texas Legislature passed Senate Bill 2337, meaningfully regulating proxy advisors like ISS and Glass Lewis when providing proxy voting recommendations concerning Texas companies.